COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
Título
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
Autor
François Bénézit, Audrey Le Bot, Stéphane Jouneau, Florian Lemaître, Charlotte Pronier, Pierre-Axel Lentz, Solène Patrat-Delon, Matthieu Revest, Vincent Thibault, Pierre Tattevin
Descripción
Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
Fecha
2020
Materia
covid-19, France, Hydroxychloroquine, 2019 novel coronavirus disease, Sarcoidosis, plasma concentration
Identificador
10.3201/eid2610.201816
Fuente
Emerging Infectious Diseases
Editor
Centers for Disease Control and Prevention
Cobertura
Medicine, Infectious and parasitic diseases
Archivos
Colección
Citación
François Bénézit, Audrey Le Bot, Stéphane Jouneau, Florian Lemaître, Charlotte Pronier, Pierre-Axel Lentz, Solène Patrat-Delon, Matthieu Revest, Vincent Thibault, Pierre Tattevin, “COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020,” SOCICT Open, consulta 19 de abril de 2026, https://www.socictopen.socict.org/items/show/5484.
Position: 17844 (17 views)